

# Oklahoma Health Care Authority

## Drug Utilization Review Board

(DUR Board)

Meeting – April 9, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority

4345 N. Lincoln

Oklahoma City, Oklahoma 73105

---

### AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

**1. Call To Order**

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

**2. Public Comment Forum**

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. March 12, 2014 DUR Minutes – Vote
- B. March 12, 2014 DUR Recommendation Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B**

- A. Medication Coverage Activity for March 2014
- B. Pharmacy Help Desk Activity for March 2014
- C. Narcotic RetroDUR

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Fiscal Year 2013 Annual Report – See Appendix C**

- A. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**6. 30-Day Notice to Prior Authorize Ophthalmic Anti-Inflammatory Medications – See Appendix D**

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

**7. Annual Review of Anti-Diabetic Medications and 30-Day Notice to Prior Authorize Farxiga™ (Dapagliflozin) and Invokana™ (Canagliflozin) – See Appendix E**

- A. Current Authorization Criteria
- B. Utilization of Anti-Diabetic Medications
- C. Prior Authorization
- D. Market News and Updates
- E. Summary
- F. Recommendations
- G. Utilization Details
- H. Product Details

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 8. Annual Review of Topical Antifungals and 30-Day Notice to Prior Authorize Luzu® (Luliconazole) – See Appendix F**
- A. Current Authorization Criteria
  - B. Utilization of Topical Antifungal Medications
  - C. Prior Authorization
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details
  - G. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 9. Annual Review of Non-Steroidal Anti-Inflammatory Drugs and 30-Day Notice to Prior Authorize Zorvolex™ (Diclofenac) and Tivorbex™ (Indomethacin) – Appendix G**
- A. Current Authorization Criteria
  - B. Utilization of NSAIDs
  - C. Prior Authorization
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details
  - G. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 10. Annual Review of Benign Prostatic Hyperplasia Medications – Appendix H**
- A. Current Authorization Criteria
  - B. Utilization of BPH Medications
  - C. Prior Authorization
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 11. Annual Review of Muscle Relaxants and 30-Day Notice to Prior Authorize Lorzone™ (Chlorzoxazone) – See Appendix I**
- A. Current Authorization Criteria
  - B. Utilization of Muscle Relaxants
  - C. Prior Authorization
  - D. Market News and Updates
  - E. COP Recommendations
  - F. Utilization Details
  - G. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 12. FDA and DEA Updates – See Appendix J**
- 13. Future Business**
- A. Annual Reviews
  - B. New Product Reviews
- 14. Adjournment**